Contact
searchSearch
HMP Global
Login

Oncology

Featured

News
Darolutamide Plus ADT and Radiotherapy Significantly Improves Metastasis-Free Survival in High-Risk Prostate Cancer
10/24/2026
Stephanie Holland
Results from the DASL-HiCaP trial demonstrated that adding darolutamide to androgen deprivation therapy and radiotherapy significantly improved metastasis-free survival in patients with very high-risk localized or biochemically...
Results from the DASL-HiCaP trial demonstrated that adding darolutamide to androgen deprivation therapy and radiotherapy significantly improved metastasis-free survival in patients with very high-risk localized or biochemically...
Results from the DASL-HiCaP...
10/24/2026
Oncology
News
Tarlatamab Plus Durvalumab Significantly Improves Overall Survival in Patients With Extensive-Stage Small Cell Lung Cancer
10/24/2026
Stephanie Holland
Results from the phase 3 DeLLphi-305 trial demonstrated that tarlatamab plus durvalumab significantly improved overall survival, progression-free survival, and objective response compared with durvalumab alone as first-line maintenance...
Results from the phase 3 DeLLphi-305 trial demonstrated that tarlatamab plus durvalumab significantly improved overall survival, progression-free survival, and objective response compared with durvalumab alone as first-line maintenance...
Results from the phase 3...
10/24/2026
Oncology
News
VOLGA Trial Demonstrates Significant Survival Benefit With Durvalumab Plus Enfortumab Vedotin in Muscle-Invasive Bladder Cancer
10/24/2026
Stephanie Holland
Results from the phase 3 VOLGA trial demonstrated that perioperative durvalumab plus neoadjuvant enfortumab vedotin significantly improved event-free and overall survival in cisplatin-ineligible or cisplatin-refusing patients with...
Results from the phase 3 VOLGA trial demonstrated that perioperative durvalumab plus neoadjuvant enfortumab vedotin significantly improved event-free and overall survival in cisplatin-ineligible or cisplatin-refusing patients with...
Results from the phase 3 VOLGA...
10/24/2026
Oncology
News
Intismeran Plus Pembrolizumab Significantly Improves Recurrence-Free Survival in Resected High-Risk Melanoma
10/24/2026
Stephanie Holland
Results from the phase 3 INTerpath-001 trial demonstrated that intismeran plus pembrolizumab significantly improved recurrence-free and distant metastasis-free survival compared with pembrolizumab alone in patients with resected high-risk...
Results from the phase 3 INTerpath-001 trial demonstrated that intismeran plus pembrolizumab significantly improved recurrence-free and distant metastasis-free survival compared with pembrolizumab alone in patients with resected high-risk...
Results from the phase 3...
10/24/2026
Oncology
Alexandra Gomez-Arteaga, MD, and Elias Jabbour, MD
Videos
CAR T-Cell Therapy and Bispecific Antibodies Reshape Treatment Sequencing in Acute Lymphoblastic Leukemia
10/24/2026
Elias Jabbour, MD; Alexandra Gomez Arteaga, MD
Alexandra Gomez-Arteaga, MD, and Elias Jabbour, MD, discuss evolving treatment strategies for adult acute lymphoblastic leukemia, highlighting earlier CAR T-cell therapy, advances in bispecific antibodies, MRD-guided treatment selection, and...
Alexandra Gomez-Arteaga, MD, and Elias Jabbour, MD, discuss evolving treatment strategies for adult acute lymphoblastic leukemia, highlighting earlier CAR T-cell therapy, advances in bispecific antibodies, MRD-guided treatment selection, and...
Alexandra Gomez-Arteaga, MD, and...
10/24/2026
Oncology
Eunice Wang, MD, and Eytan Stein, MD
Videos
Menin Inhibitors Advance Targeted Treatment Strategies in NPM1-Mutated and KMT2A-Rearranged Acute Myeloid Leukemia
10/24/2026
Eytan Stein, MD
Eunice Wang, MD, and Eytan Stein, MD, discuss advances in menin inhibitor therapy for acute myeloid leukemia, highlighting the clinical activity of revumenib and ziftomenib, emerging combination strategies, mechanisms of acquired resistance,...
Eunice Wang, MD, and Eytan Stein, MD, discuss advances in menin inhibitor therapy for acute myeloid leukemia, highlighting the clinical activity of revumenib and ziftomenib, emerging combination strategies, mechanisms of acquired resistance,...
Eunice Wang, MD, and Eytan...
10/24/2026
Oncology
Paul Richardson, MD
Videos
Emerging Immunotherapies and Targeted Agents Advance Treatment of High-Risk Multiple Myeloma
10/24/2026
Paul Richardson, MD, discusses advances in high-risk multiple myeloma management, highlighting genomic and functional risk stratification, frontline quadruplet regimens, emerging immunotherapies, and novel CELMoDs such as iberdomide and...
Paul Richardson, MD, discusses advances in high-risk multiple myeloma management, highlighting genomic and functional risk stratification, frontline quadruplet regimens, emerging immunotherapies, and novel CELMoDs such as iberdomide and...
Paul Richardson, MD, discusses...
10/24/2026
Oncology
Pinkal Desai, MD
Videos
MRD-Guided Risk Stratification Refines Transplant Decisions in Patients With Acute Myeloid Leukemia
10/24/2026
Pinkal Desai, MD
Pinkal Desai, MD, discusses post-remission treatment strategies in acute myeloid leukemia, highlighting how molecular risk classification, measurable residual disease monitoring, and transplant-related risk guide allogenic stem cell...
Pinkal Desai, MD, discusses post-remission treatment strategies in acute myeloid leukemia, highlighting how molecular risk classification, measurable residual disease monitoring, and transplant-related risk guide allogenic stem cell...
Pinkal Desai, MD, discusses...
10/24/2026
Oncology
Joshua Richter, MD
Videos
MRD Assessment Advances Risk Stratification and Treatment Decision-Making in Multiple Myeloma
10/24/2026
Joshua Richter, MD
Joshua Richter, MD, discusses the evolving role of measurable residual disease assessment in multiple myeloma, highlighting its prognostic value, growing importance in clinical trials and regulatory decisions, and the need for prospective...
Joshua Richter, MD, discusses the evolving role of measurable residual disease assessment in multiple myeloma, highlighting its prognostic value, growing importance in clinical trials and regulatory decisions, and the need for prospective...
Joshua Richter, MD, discusses...
10/24/2026
Oncology
John Mascarenhas, MD
Videos
JAK Inhibitors and Emerging Combination Strategies Advance Personalized Treatment in Myelofibrosis
10/24/2026
John Mascarenhas, MD
John Mascarenhas, MD, discusses advances in myelofibrosis treatment, highlighting individualized JAK inhibitor selection, emerging CALR-targeted therapies, novel combination strategies involving pelabresib and selinexor, and ongoing efforts...
John Mascarenhas, MD, discusses advances in myelofibrosis treatment, highlighting individualized JAK inhibitor selection, emerging CALR-targeted therapies, novel combination strategies involving pelabresib and selinexor, and ongoing efforts...
John Mascarenhas, MD, discusses...
10/24/2026
Oncology
FDA Approval
FDA Grants Full Approval to Pembrolizumab for Patients With Tumor Mutational Burden-High Solid Tumors
10/23/2026
Emily Estrada
Based on results from the KEYNOTE-158 trial, the FDA converted pembrolizumab’s accelerated approval to traditional approval for adult and pediatric patients with previously treated unresectable or metastatic tumor mutational burden-high...
Based on results from the KEYNOTE-158 trial, the FDA converted pembrolizumab’s accelerated approval to traditional approval for adult and pediatric patients with previously treated unresectable or metastatic tumor mutational burden-high...
Based on results from the...
10/23/2026
Oncology

Videos

Alexandra Gomez-Arteaga, MD, and Elias Jabbour, MD
Videos
CAR T-Cell Therapy and Bispecific Antibodies Reshape Treatment Sequencing in Acute Lymphoblastic Leukemia
10/24/2026
Elias Jabbour, MD; Alexandra Gomez Arteaga, MD
Alexandra Gomez-Arteaga, MD, and Elias Jabbour, MD, discuss evolving treatment strategies for adult acute lymphoblastic leukemia, highlighting earlier CAR T-cell therapy, advances in bispecific antibodies, MRD-guided treatment selection, and...
Alexandra Gomez-Arteaga, MD, and Elias Jabbour, MD, discuss evolving treatment strategies for adult acute lymphoblastic leukemia, highlighting earlier CAR T-cell therapy, advances in bispecific antibodies, MRD-guided treatment selection, and...
Alexandra Gomez-Arteaga, MD, and...
10/24/2026
Oncology
Eunice Wang, MD, and Eytan Stein, MD
Videos
Menin Inhibitors Advance Targeted Treatment Strategies in NPM1-Mutated and KMT2A-Rearranged Acute Myeloid Leukemia
10/24/2026
Eytan Stein, MD
Eunice Wang, MD, and Eytan Stein, MD, discuss advances in menin inhibitor therapy for acute myeloid leukemia, highlighting the clinical activity of revumenib and ziftomenib, emerging combination strategies, mechanisms of acquired resistance,...
Eunice Wang, MD, and Eytan Stein, MD, discuss advances in menin inhibitor therapy for acute myeloid leukemia, highlighting the clinical activity of revumenib and ziftomenib, emerging combination strategies, mechanisms of acquired resistance,...
Eunice Wang, MD, and Eytan...
10/24/2026
Oncology
Paul Richardson, MD
Videos
Emerging Immunotherapies and Targeted Agents Advance Treatment of High-Risk Multiple Myeloma
10/24/2026
Paul Richardson, MD, discusses advances in high-risk multiple myeloma management, highlighting genomic and functional risk stratification, frontline quadruplet regimens, emerging immunotherapies, and novel CELMoDs such as iberdomide and...
Paul Richardson, MD, discusses advances in high-risk multiple myeloma management, highlighting genomic and functional risk stratification, frontline quadruplet regimens, emerging immunotherapies, and novel CELMoDs such as iberdomide and...
Paul Richardson, MD, discusses...
10/24/2026
Oncology
Pinkal Desai, MD
Videos
MRD-Guided Risk Stratification Refines Transplant Decisions in Patients With Acute Myeloid Leukemia
10/24/2026
Pinkal Desai, MD
Pinkal Desai, MD, discusses post-remission treatment strategies in acute myeloid leukemia, highlighting how molecular risk classification, measurable residual disease monitoring, and transplant-related risk guide allogenic stem cell...
Pinkal Desai, MD, discusses post-remission treatment strategies in acute myeloid leukemia, highlighting how molecular risk classification, measurable residual disease monitoring, and transplant-related risk guide allogenic stem cell...
Pinkal Desai, MD, discusses...
10/24/2026
Oncology
Joshua Richter, MD
Videos
MRD Assessment Advances Risk Stratification and Treatment Decision-Making in Multiple Myeloma
10/24/2026
Joshua Richter, MD
Joshua Richter, MD, discusses the evolving role of measurable residual disease assessment in multiple myeloma, highlighting its prognostic value, growing importance in clinical trials and regulatory decisions, and the need for prospective...
Joshua Richter, MD, discusses the evolving role of measurable residual disease assessment in multiple myeloma, highlighting its prognostic value, growing importance in clinical trials and regulatory decisions, and the need for prospective...
Joshua Richter, MD, discusses...
10/24/2026
Oncology
John Mascarenhas, MD
Videos
JAK Inhibitors and Emerging Combination Strategies Advance Personalized Treatment in Myelofibrosis
10/24/2026
John Mascarenhas, MD
John Mascarenhas, MD, discusses advances in myelofibrosis treatment, highlighting individualized JAK inhibitor selection, emerging CALR-targeted therapies, novel combination strategies involving pelabresib and selinexor, and ongoing efforts...
John Mascarenhas, MD, discusses advances in myelofibrosis treatment, highlighting individualized JAK inhibitor selection, emerging CALR-targeted therapies, novel combination strategies involving pelabresib and selinexor, and ongoing efforts...
John Mascarenhas, MD, discusses...
10/24/2026
Oncology
Videos
Individualizing First-Line Immunotherapy in Advanced cSCC: What Tolerability Trade-Offs Exist and How Do They Shape Real-World Use?
10/21/2026
Sunandana Chandra, MD; Solly Chedid, MD; Bahar Dasgeb, MD
10/21/2026
Oncology
Videos
Individualizing First-Line Immunotherapy in Advanced cSCC: How Should Pivotal Trial Data Guide First-Line Treatment Selection?
10/21/2026
Sunandana Chandra, MD; Solly Chedid, MD; Bahar Dasgeb, MD
In a fit, treatment-naive patient with good performance status, does the mature, multi-year efficacy and safety data behind anti-PD-1 agents outweigh the rationale for a newer, selective anti-PD-L1 option? Experts debate how follow-up...
In a fit, treatment-naive patient with good performance status, does the mature, multi-year efficacy and safety data behind anti-PD-1 agents outweigh the rationale for a newer, selective anti-PD-L1 option? Experts debate how follow-up...
In a fit, treatment-naive...
10/21/2026
Oncology
Videos
Immune Checkpoint Inhibition in Advanced cSCC: Perspectives From Clinical Practice
10/19/2026
David Portnoy, MD, FACP
10/19/2026
Oncology
Catherine Diefenbach, MD
Videos
Optimizing First-Line Treatment Selection Across in Early- and Advanced-Stage Hodgkin Lymphoma
10/15/2026
Catherine Diefenbach, MD
Catherine Diefenbach, MD, discusses evolving first-line treatment options for patients with classical Hodgkin lymphoma, highlighting findings from the S1826 and HD21 trials, the integration of nivolumab and AVD and brentuximab vedotin-based...
Catherine Diefenbach, MD, discusses evolving first-line treatment options for patients with classical Hodgkin lymphoma, highlighting findings from the S1826 and HD21 trials, the integration of nivolumab and AVD and brentuximab vedotin-based...
Catherine Diefenbach, MD,...
10/15/2026
Oncology

Insights From the ASCO Annual Meeting

News
First-in-Class Hepcidin Inhibitor DISC-0974 Demonstrates Activity in Myelofibrosis-Associated Anemia
07/09/2026
Stephanie Holland
Results from the ongoing, phase 2 RALLY-MF trial demonstrated that DISC-0974 produced meaningful hematologic responses and improved fatigue in patients with myelofibrosis-associated anemia, supporting hepcidin inhibition as a potential...
Results from the ongoing, phase 2 RALLY-MF trial demonstrated that DISC-0974 produced meaningful hematologic responses and improved fatigue in patients with myelofibrosis-associated anemia, supporting hepcidin inhibition as a potential...
Results from the ongoing, phase...
07/09/2026
Oncology
News
Imetelstat Maintains Overall Survival Advantage Over Best Available Therapy in JAK Inhibitor–Relapsed or Refractory Myelofibrosis
07/09/2026
Stephanie Holland
Updated results from a post hoc analysis demonstrated that imetelstat continued to improve overall survival compared with best available therapy in patients with JAK inhibitor relapsed or refractory myelofibrosis, despite substantial changes...
Updated results from a post hoc analysis demonstrated that imetelstat continued to improve overall survival compared with best available therapy in patients with JAK inhibitor relapsed or refractory myelofibrosis, despite substantial changes...
Updated results from a post hoc...
07/09/2026
Oncology
Ramaswamy Govindan, MD
Videos
Adjuvant Erlotinib Following Complete Resection of EGFR-Mutant Non-Small Cell Lung Cancer Improves Disease Free Survival But Not Overall Survival
06/29/2026
Ramaswamy Govindan, MD
Ramaswamy Govindan, MD, discusses results from the ALCHEMIST trial evaluating adjuvant erlotinib in resected EGFR-mutant non–small cell lung cancer and the potential for ongoing biomarker studies to identify patients most likely to benefit...
Ramaswamy Govindan, MD, discusses results from the ALCHEMIST trial evaluating adjuvant erlotinib in resected EGFR-mutant non–small cell lung cancer and the potential for ongoing biomarker studies to identify patients most likely to benefit...
Ramaswamy Govindan, MD,...
06/29/2026
Oncology
Erika Hamilton, MD
Videos
Tucatinib Demonstrates Consistent Benefit Across First-Line HER2-Positive Metastatic Breast Cancer Populations
06/26/2026
Erika Hamilton, MD
Erika Hamilton, MD, discusses updated results from the HER2CLIMB-05 trial showing that tucatinib added to trastuzumab and pertuzumab maintenance therapy improved outcomes across multiple clinically relevant subgroups of patients with...
Erika Hamilton, MD, discusses updated results from the HER2CLIMB-05 trial showing that tucatinib added to trastuzumab and pertuzumab maintenance therapy improved outcomes across multiple clinically relevant subgroups of patients with...
Erika Hamilton, MD, discusses...
06/26/2026
Oncology
Bjørn Henning Grønberg, MD, PhD
Videos
Concurrent Radiotherapy, Chemotherapy, and Durvalumab Does Not Improve Outcomes in Extensive-Stage Small Cell Lung Cancer
06/26/2026
Bjørn Henning Grønberg, MD, PhD
Bjørn Henning Grønberg, MD, PhD, discusses results from a phase 3 randomized trial evaluating the addition of concurrent thoracic radiotherapy to platinum/etoposide chemotherapy plus durvalumab in patients with extensive-stage small cell lung...
Bjørn Henning Grønberg, MD, PhD, discusses results from a phase 3 randomized trial evaluating the addition of concurrent thoracic radiotherapy to platinum/etoposide chemotherapy plus durvalumab in patients with extensive-stage small cell lung...
Bjørn Henning Grønberg, MD, PhD,...
06/26/2026
Oncology
Peter O’Donnell, MD
Videos
Health-Related Quality of Life Preserved with Neoadjuvant and Adjuvant Enfortumab Vedotin plus Pembrolizumab in Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer
06/26/2026
Peter O'Donnell, MD
Peter O’Donnell, MD, of the University of Chicago, discusses health-related quality-of-life (HRQoL) findings from the phase 3 KEYNOTE-905 study evaluating perioperative enfortumab vedotin plus pembrolizumab in patients with muscle-invasive...
Peter O’Donnell, MD, of the University of Chicago, discusses health-related quality-of-life (HRQoL) findings from the phase 3 KEYNOTE-905 study evaluating perioperative enfortumab vedotin plus pembrolizumab in patients with muscle-invasive...
Peter O’Donnell, MD, of the...
06/26/2026
Oncology
Sanjay Popat, PhD, FRCP
Videos
Pralsetinib Shows Improved Response in RET Fusion–Positive Advanced or Metastatic Non–Small Cell Lung Cancer
06/25/2026
Sanjay Popat, PhD, FRCP
Sanjay Popat, PhD, FRCP, medical oncologist at The Royal Marsden Hospital in London, England, discusses results from the phase 3 AcceleRET-Lung trial evaluating first-line pralsetinib versus standard-of-care histology-specific chemotherapy...
Sanjay Popat, PhD, FRCP, medical oncologist at The Royal Marsden Hospital in London, England, discusses results from the phase 3 AcceleRET-Lung trial evaluating first-line pralsetinib versus standard-of-care histology-specific chemotherapy...
Sanjay Popat, PhD, FRCP, medical...
06/25/2026
Oncology
Walter Weber, MD
Videos
Prepectoral Implant Placement Improves Long-Term Quality of Life After Breast Reconstruction
06/24/2026
Walter Weber, MD
Walter Weber, MD, discusses results from the phase 3 PREPEC trial showing that prepectoral implant-based breast reconstruction significantly improved long-term quality of life and physical well-being compared with subpectoral reconstruction...
Walter Weber, MD, discusses results from the phase 3 PREPEC trial showing that prepectoral implant-based breast reconstruction significantly improved long-term quality of life and physical well-being compared with subpectoral reconstruction...
Walter Weber, MD, discusses...
06/24/2026
Oncology
Timothy Cloughesy, MD
Videos
Vorasidenib Maintains Durable Clinical Benefit With Consistent Safety in IDH-Mutated Glioma
06/24/2026
Timothy Cloughesy, MD
Timothy Cloughesy, MD, discusses updated results from the INDIGO trial showing durable disease control, prolonged progression-free survival, and sustained safety with vorasidenib in patients with IDH-mutant grade 2 gliomas.
Timothy Cloughesy, MD, discusses updated results from the INDIGO trial showing durable disease control, prolonged progression-free survival, and sustained safety with vorasidenib in patients with IDH-mutant grade 2 gliomas.
Timothy Cloughesy, MD, discusses...
06/24/2026
Oncology
Peter Schmid, MD, PhD
Videos
Giredestrant Improves Outcomes Regardless of Menopausal Status in Early Breast Cancer
06/24/2026
Peter Schmid, MD, PhD
Peter Schmid, MD, PhD, discusses subgroup analysis results from the lidERA trial showing that giredestrant improved invasive disease-free and distant recurrence-free survival across premenopausal and postmenopausal patients with ER-positive,...
Peter Schmid, MD, PhD, discusses subgroup analysis results from the lidERA trial showing that giredestrant improved invasive disease-free and distant recurrence-free survival across premenopausal and postmenopausal patients with ER-positive,...
Peter Schmid, MD, PhD, discusses...
06/24/2026
Oncology

Insights From the ESMO Congress

News
Darolutamide Plus ADT and Radiotherapy Significantly Improves Metastasis-Free Survival in High-Risk Prostate Cancer
10/24/2026
Stephanie Holland
Results from the DASL-HiCaP trial demonstrated that adding darolutamide to androgen deprivation therapy and radiotherapy significantly improved metastasis-free survival in patients with very high-risk localized or biochemically...
Results from the DASL-HiCaP trial demonstrated that adding darolutamide to androgen deprivation therapy and radiotherapy significantly improved metastasis-free survival in patients with very high-risk localized or biochemically...
Results from the DASL-HiCaP...
10/24/2026
Oncology
News
Tarlatamab Plus Durvalumab Significantly Improves Overall Survival in Patients With Extensive-Stage Small Cell Lung Cancer
10/24/2026
Stephanie Holland
Results from the phase 3 DeLLphi-305 trial demonstrated that tarlatamab plus durvalumab significantly improved overall survival, progression-free survival, and objective response compared with durvalumab alone as first-line maintenance...
Results from the phase 3 DeLLphi-305 trial demonstrated that tarlatamab plus durvalumab significantly improved overall survival, progression-free survival, and objective response compared with durvalumab alone as first-line maintenance...
Results from the phase 3...
10/24/2026
Oncology
News
VOLGA Trial Demonstrates Significant Survival Benefit With Durvalumab Plus Enfortumab Vedotin in Muscle-Invasive Bladder Cancer
10/24/2026
Stephanie Holland
Results from the phase 3 VOLGA trial demonstrated that perioperative durvalumab plus neoadjuvant enfortumab vedotin significantly improved event-free and overall survival in cisplatin-ineligible or cisplatin-refusing patients with...
Results from the phase 3 VOLGA trial demonstrated that perioperative durvalumab plus neoadjuvant enfortumab vedotin significantly improved event-free and overall survival in cisplatin-ineligible or cisplatin-refusing patients with...
Results from the phase 3 VOLGA...
10/24/2026
Oncology
News
Intismeran Plus Pembrolizumab Significantly Improves Recurrence-Free Survival in Resected High-Risk Melanoma
10/24/2026
Stephanie Holland
Results from the phase 3 INTerpath-001 trial demonstrated that intismeran plus pembrolizumab significantly improved recurrence-free and distant metastasis-free survival compared with pembrolizumab alone in patients with resected high-risk...
Results from the phase 3 INTerpath-001 trial demonstrated that intismeran plus pembrolizumab significantly improved recurrence-free and distant metastasis-free survival compared with pembrolizumab alone in patients with resected high-risk...
Results from the phase 3...
10/24/2026
Oncology
Stephen Freedland, MD
Videos
Enzalutamide Plus Androgen Deprivation Therapy in Biochemically Recurrent Prostate Cancer
12/02/2025
Stephen J. Freedland, MD
Stephen Freedland, MD, discusses final overall survival results from the EMBARK study, which evaluated enzalutamide plus androgen deprivation therapy in patients with high-risk biochemical recurrence and negative conventional imaging.
Stephen Freedland, MD, discusses final overall survival results from the EMBARK study, which evaluated enzalutamide plus androgen deprivation therapy in patients with high-risk biochemical recurrence and negative conventional imaging.
Stephen Freedland, MD, discusses...
12/02/2025
Oncology
Brian Slomovitz, MD
Videos
Relacorilant Plus Nab-Paclitaxel in Recurrent Platinum-Resistant Ovarian Cancer
12/02/2025
Brian M. Slomovitz, MD, MS
Brian Slomovitz, MD, discusses updated findings from the ROSELLA trial evaluating relacorilant plus nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.
Brian Slomovitz, MD, discusses updated findings from the ROSELLA trial evaluating relacorilant plus nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.
Brian Slomovitz, MD, discusses...
12/02/2025
Oncology
Pasi Jänne, MD, PhD
Videos
Osimertinib Plus Chemotherapy Provides Broad Survival Benefit in EGFR-Mutant NSCLC
12/02/2025
Pasi Jänne, MD, PhD
Pasi Jänne, MD, PhD, discusses subgroup analysis results from the FLAURA2 trial evaluating osimertinib plus platinum-pemetrexed chemotherapy in patients with newly diagnosed EGFR-mutant non-small cell lung cancer.
Pasi Jänne, MD, PhD, discusses subgroup analysis results from the FLAURA2 trial evaluating osimertinib plus platinum-pemetrexed chemotherapy in patients with newly diagnosed EGFR-mutant non-small cell lung cancer.
Pasi Jänne, MD, PhD, discusses...
12/02/2025
Oncology
David Goldstein, MD
Videos
Regorafenib Plus Nivolumab Fails to Improve Outcomes in Gastric or Gastroesophageal Cancer
12/02/2025
David Goldstein, MD
David Goldstein, MD, discusses results from the INTEGRATE study which assessed regorafenib plus nivolumab in previously treated patients with gastric or gastroesophageal cancer.
David Goldstein, MD, discusses results from the INTEGRATE study which assessed regorafenib plus nivolumab in previously treated patients with gastric or gastroesophageal cancer.
David Goldstein, MD, discusses...
12/02/2025
Oncology
Sara Lonardi, MD
Videos
Dual Immunotherapy Delivers Durable Benefit in MSI-H/dMMR Metastatic Colorectal Cancer
11/13/2025
Sara Lonardi, MD
Sara Lonardi, MD, shares updated results from CheckMate 8HW comparing nivolumab plus ipilimumab with nivolumab alone or chemotherapy as first-line therapy for patients with MSI-H/dMMR metastatic colorectal cancer.
Sara Lonardi, MD, shares updated results from CheckMate 8HW comparing nivolumab plus ipilimumab with nivolumab alone or chemotherapy as first-line therapy for patients with MSI-H/dMMR metastatic colorectal cancer.
Sara Lonardi, MD, shares updated...
11/13/2025
Oncology
Sanjay Popat, MD, PhD
Videos
First-Line Zongertinib Demonstrates Promise in HER2-Mutated NSCLC
11/13/2025
Sanjay Popat, MD
Sanjay Popat, MD, PhD, discusses results from the phase 2 BEAMION-LUNG 1 trial evaluating zongertinib as a first-line treatment option for patients with advanced HER2-mutated non-small cell lung cancer.
Sanjay Popat, MD, PhD, discusses results from the phase 2 BEAMION-LUNG 1 trial evaluating zongertinib as a first-line treatment option for patients with advanced HER2-mutated non-small cell lung cancer.
Sanjay Popat, MD, PhD, discusses...
11/13/2025
Oncology

Live Meetings

Recent News

News
Darolutamide Plus ADT and Radiotherapy Significantly Improves Metastasis-Free Survival in High-Risk Prostate Cancer
10/24/2026
Stephanie Holland
Results from the DASL-HiCaP trial demonstrated that adding darolutamide to androgen deprivation therapy and radiotherapy significantly improved metastasis-free survival in patients with very high-risk localized or biochemically...
Results from the DASL-HiCaP trial demonstrated that adding darolutamide to androgen deprivation therapy and radiotherapy significantly improved metastasis-free survival in patients with very high-risk localized or biochemically...
Results from the DASL-HiCaP...
10/24/2026
Oncology
News
Tarlatamab Plus Durvalumab Significantly Improves Overall Survival in Patients With Extensive-Stage Small Cell Lung Cancer
10/24/2026
Stephanie Holland
Results from the phase 3 DeLLphi-305 trial demonstrated that tarlatamab plus durvalumab significantly improved overall survival, progression-free survival, and objective response compared with durvalumab alone as first-line maintenance...
Results from the phase 3 DeLLphi-305 trial demonstrated that tarlatamab plus durvalumab significantly improved overall survival, progression-free survival, and objective response compared with durvalumab alone as first-line maintenance...
Results from the phase 3...
10/24/2026
Oncology
News
VOLGA Trial Demonstrates Significant Survival Benefit With Durvalumab Plus Enfortumab Vedotin in Muscle-Invasive Bladder Cancer
10/24/2026
Stephanie Holland
Results from the phase 3 VOLGA trial demonstrated that perioperative durvalumab plus neoadjuvant enfortumab vedotin significantly improved event-free and overall survival in cisplatin-ineligible or cisplatin-refusing patients with...
Results from the phase 3 VOLGA trial demonstrated that perioperative durvalumab plus neoadjuvant enfortumab vedotin significantly improved event-free and overall survival in cisplatin-ineligible or cisplatin-refusing patients with...
Results from the phase 3 VOLGA...
10/24/2026
Oncology
News
Intismeran Plus Pembrolizumab Significantly Improves Recurrence-Free Survival in Resected High-Risk Melanoma
10/24/2026
Stephanie Holland
Results from the phase 3 INTerpath-001 trial demonstrated that intismeran plus pembrolizumab significantly improved recurrence-free and distant metastasis-free survival compared with pembrolizumab alone in patients with resected high-risk...
Results from the phase 3 INTerpath-001 trial demonstrated that intismeran plus pembrolizumab significantly improved recurrence-free and distant metastasis-free survival compared with pembrolizumab alone in patients with resected high-risk...
Results from the phase 3...
10/24/2026
Oncology
FDA Approval
FDA Grants Full Approval to Pembrolizumab for Patients With Tumor Mutational Burden-High Solid Tumors
10/23/2026
Emily Estrada
Based on results from the KEYNOTE-158 trial, the FDA converted pembrolizumab’s accelerated approval to traditional approval for adult and pediatric patients with previously treated unresectable or metastatic tumor mutational burden-high...
Based on results from the KEYNOTE-158 trial, the FDA converted pembrolizumab’s accelerated approval to traditional approval for adult and pediatric patients with previously treated unresectable or metastatic tumor mutational burden-high...
Based on results from the...
10/23/2026
Oncology
FDA Approval
FDA Approves Dostarlimab for Patients With MSI-H/dMMR Locally Advanced Rectal Cancer
10/19/2026
Emily Estrada
The FDA granted accelerated approval to dostarlimab for patients with stage II/III MSI-H/dMMR locally advanced rectal cancer, establishing an immunotherapy-based treatment option supported by sustained clinical complete responses and the...
The FDA granted accelerated approval to dostarlimab for patients with stage II/III MSI-H/dMMR locally advanced rectal cancer, establishing an immunotherapy-based treatment option supported by sustained clinical complete responses and the...
The FDA granted accelerated...
10/19/2026
Oncology
FDA Approval
FDA Expands Nogapendekin Alfa Inbakicept Plus Bacillus Calmette-Guérin Approval to Include High-Grade Papillary-Only Bladder Cancer
10/14/2026
Emily Estrada
The FDA expanded the indication for nogapendekin alfa inbakicept plus Bacillus Calmette-Guérin (BCG) to include patients with high-grade papillary-only, BCG-unresponsive non-muscle-invasive bladder cancer, extending treatment eligibility...
The FDA expanded the indication for nogapendekin alfa inbakicept plus Bacillus Calmette-Guérin (BCG) to include patients with high-grade papillary-only, BCG-unresponsive non-muscle-invasive bladder cancer, extending treatment eligibility...
The FDA expanded the indication...
10/14/2026
Oncology
News
Pegylated Liposomal Doxorubicin Improves Progression-Free Survival in Patients With Advanced Desmoid Tumors
10/09/2026
Emily Estrada
Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly prolonged progression-free survival and objective response compared with placebo in patients with advanced or refractory desmoid tumors, supporting...
Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly prolonged progression-free survival and objective response compared with placebo in patients with advanced or refractory desmoid tumors, supporting...
Results from a phase 3 trial...
10/09/2026
Oncology
News
Iberdomide Plus Daratumumab and Dexamethasone Significantly Improves PFS in Relapsed or Refractory Multiple Myeloma
10/08/2026
Stephanie Holland
Topline results from the phase 3 EXCALIBER-RRMM trial demonstrated significantly prolonged progression-free survival with iberdomide plus daratumumab and dexamethasone compared with daratumumab, bortezomib, and dexamethasone in...
Topline results from the phase 3 EXCALIBER-RRMM trial demonstrated significantly prolonged progression-free survival with iberdomide plus daratumumab and dexamethasone compared with daratumumab, bortezomib, and dexamethasone in...
Topline results from the phase 3...
10/08/2026
Oncology
News
Cytarabine Induction Followed by Azacitidine and Lenalidomide Shows Activity in Very-High-Risk Myelodysplastic Syndromes
10/08/2026
Emily Estrada
Results from a small study evaluating a resource-adapted treatment strategy for very-high-risk myelodysplastic syndromes demonstrated responses with cytarabine induction followed by azacitidine and lenalidomide, supporting further...
Results from a small study evaluating a resource-adapted treatment strategy for very-high-risk myelodysplastic syndromes demonstrated responses with cytarabine induction followed by azacitidine and lenalidomide, supporting further...
Results from a small study...
10/08/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use